GASC
MCID: GST053
MIFTS: 79

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 58 39 12 54 76 38 56 15
Stomach Cancer 12 77 54 76 30 44 15
Stomach Carcinoma 12 54 15 74
Gastric Carcinoma 12 56 15 17
Malignant Tumor of Lesser Curve of Stomach 12 74
Malignant Neoplasm of Body of Stomach 12 74
Stomach Neoplasms 45 74
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Malignant Neoplasm of Stomach 74
Gastric Cancer Intestinal 76
Gastric Cancer, Somatic 58
Adult Stomach Carcinoma 54
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 54
Ca Body - Stomach 12
Gastric Neoplasm 12
Stomach Neoplasm 17
Cancer, Gastric 41
Gasc 76

Characteristics:

HPO:

33
gastric cancer:
Inheritance somatic mutation


Classifications:



Summaries for Gastric Cancer

NIH Rare Diseases : 54 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM : 58 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : 44 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 77 Stomach cancer, also known as gastric cancer, is a cancer which develops from the lining of the stomach.... more...

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 632)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 33.7 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
2 colorectal cancer 32.5 APC CTNNB1 ERBB2 KRAS MIR106B MIR141
3 adenocarcinoma 32.4 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
4 breast cancer 32.3 APC CTNNB1 ERBB2 FGFR2 KRAS MIR141
5 prostate cancer 31.9 CTNNB1 ERBB2 FGFR2 KLF6 KRAS MIR106B
6 hepatocellular carcinoma 31.9 APC CTNNB1 KRAS MIR106B MIR141 MIR145
7 esophageal cancer 31.8 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR34A
8 adenoma 31.8 APC CTNNB1 KRAS MUTYH
9 lung cancer 31.8 ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
10 pancreatic cancer 31.6 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR221
11 familial adenomatous polyposis 31.5 APC CTNNB1 KRAS MUTYH
12 melanoma 31.4 MIR141 MIR200C MIR221 MIR27A MIR34A
13 cholangiocarcinoma 31.4 CTNNB1 ERBB2 KRAS MIR141 MIR21 PIK3CA
14 lung cancer susceptibility 3 31.3 APC CTNNB1 ERBB2 KLF6 KRAS PIK3CA
15 lynch syndrome 31.3 APC CTNNB1 KRAS MUTYH
16 bladder cancer 31.2 ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
17 cervical cancer 31.1 CTNNB1 ERBB2 IRF1 MIR21 PIK3CA
18 glioma 31.1 ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
19 large intestine cancer 31.0 APC CTNNB1 ERBB2 KRAS MUTYH PIK3CA
20 respiratory system cancer 30.9 CTNNB1 ERBB2 KRAS PIK3CA
21 adenoid cystic carcinoma 30.8 CTNNB1 ERBB2 KRAS PIK3CA
22 intrahepatic cholangiocarcinoma 30.8 CTNNB1 FGFR2 KRAS
23 colorectal adenoma 30.8 APC CTNNB1 KRAS MUTYH
24 intestinal disease 30.8 CTNNB1 KRAS MUTYH PIK3CA
25 nonalcoholic fatty liver disease 30.8 MIR200C MIR203A MIR21 MIR27A MIR34A
26 kidney cancer 30.7 MIR106B MIR141 MIR200C MIR21 MIR27A
27 pancreatic ductal adenocarcinoma 30.7 MIR141 MIR145 MIR203A MIR21 MIR221
28 leukemia, chronic lymphocytic 2 30.7 KRAS MIR106B MIR145 MIR34A
29 ovarian cancer 1 30.7 ERBB2 KRAS PIK3CA
30 desmoid tumor 30.5 APC CTNNB1
31 attenuated familial adenomatous polyposis 30.4 APC MUTYH
32 gastric cancer, hereditary diffuse 12.8
33 diffuse gastric cancer 12.5
34 microinvasive gastric cancer 12.5
35 stomach carcinoma in situ 12.3
36 epstein-barr virus-associated gastric carcinoma 12.3
37 carcinoma of stomach, salivary gland type 12.2
38 undifferentiated carcinoma of stomach 12.2
39 gastric adenocarcinoma and proximal polyposis of the stomach 11.4
40 li-fraumeni syndrome 11.4
41 li-fraumeni syndrome 2 11.4
42 ovarian cancer 11.1 CTNNB1 ERBB2 KRAS MIR106B MIR141 MIR145
43 gastric squamous cell carcinoma 11.1
44 gastric adenosquamous carcinoma 11.1
45 gastric small cell carcinoma 11.1
46 stomach cancer, childhood 11.1
47 gastric linitis plastica 11.1
48 gastric fundus cancer 11.1
49 gastric body carcinoma 11.1
50 small intestine cancer 11.0

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

33
# Description HPO Frequency HPO Source Accession
1 stomach cancer 33 HP:0012126
2 increased level of l-fucose in urine 33 HP:0410067

Clinical features from OMIM:

613659

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 APC CTNNB1 ERBB2 FGFR2 IRF1 KLF6
2 neoplasm MP:0002006 9.23 APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
2
Herceptin 19 50 TRASTUZUMAB Genentech October 1998
3
Iressa 19 50 GEFITINIB AstraZeneca May 2003

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
2
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
3
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
4
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 6857599 5310940 9887054 43805
5
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
6
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
7
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
8
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
9
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
10
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
11
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
14
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Iron Approved, Experimental Phase 4,Phase 3,Not Applicable 7439-89-6, 15438-31-0 23925 27284
17
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
18
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
19
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
20
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
21
Tetracycline Approved, Vet_approved Phase 4,Phase 3 60-54-8 5353990
22
Metronidazole Approved Phase 4,Phase 3,Phase 1 443-48-1 4173
23
Histamine Approved, Investigational Phase 4,Phase 1,Not Applicable 51-45-6 774
24
Famotidine Approved Phase 4,Phase 1 76824-35-6 3325
25
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
26
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 138530-94-6, 103577-45-3 9578005
27
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
28
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 73590-58-6 4594
29
Etomidate Approved Phase 4 33125-97-2 36339 667484
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
31
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
32
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
33
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
34
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
35
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
36
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 441203 84093 2767
37
Docetaxel Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 114977-28-5 148124
38
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
39
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
40
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
41
Floxuridine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-91-9 5790
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
43
Simethicone Approved Phase 4 8050-81-5
44
Morphine Approved, Investigational Phase 4 57-27-2 5288826
45
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
46
Coal tar Approved Phase 4 8007-45-2
47
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
48
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
49
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
50
Pasireotide Approved Phase 4,Phase 1 396091-73-9 9941444

Interventional clinical trials:

(show top 50) (show all 1931)
# Name Status NCT ID Phase Drugs
1 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
2 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
3 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
4 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
5 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
6 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
7 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
8 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
9 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
10 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
11 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
13 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
14 A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized,Cross-over Study Unknown status NCT02930616 Phase 4
15 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
16 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
17 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
18 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
19 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
20 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
21 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
22 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
23 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
24 Combined Use of Etomidate and Propofol in Painless Gastroscopy. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
25 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
26 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
27 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
28 Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
29 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
30 Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
31 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia Completed NCT01471756 Phase 4
32 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
33 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
34 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
35 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
36 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
37 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
38 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
39 Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
40 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
41 Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
42 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
43 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
44 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
45 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
46 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
47 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
48 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
49 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
50 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 30

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

42
Lymph Node, Liver, Lung, Testes, Breast, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

20
The Stomach

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 15474)
# Title Authors Year
1
New metastatic lymph node classification for early gastric cancer should differ from those for advanced gastric adenocarcinoma: Results based on the SEER database. ( 30705892 )
2019
2
The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: a French national database FREGAT. ( 30734393 )
2019
3
Correction: Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer. ( 30844907 )
2019
4
A Diagnostically Challenging Case of Autoimmune Pancreatitis Due to Contamination of the Pathological Specimen with Early Gastric Cancer. ( 30626846 )
2019
5
Long noncoding RNA microvascular invasion in hepatocellular carcinoma is an indicator of poor prognosis and a potential therapeutic target in gastric cancer. ( 30880767 )
2019
6
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. ( 30626829 )
2019
7
Nivolumab-related Sclerosing Cholangitis in Gastric Cancer. ( 30626840 )
2019
8
Response: patient blood management strategies for iron-deficiency anemia management in gastric cancer. ( 30720606 )
2019
9
Patient Blood Management strategies for iron deficiency anemia management in gastric cancer. ( 30829765 )
2019
10
Gastric cancer and paraneoplastic dermatomyositis as complications of an unrecognized juvenile polyposis syndrome. ( 30873576 )
2019
11
Establishing a center of excellence for hereditary diffuse gastric cancer syndrome. ( 30618047 )
2019
12
Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). ( 30745422 )
2019
13
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. ( 30870726 )
2019
14
INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. ( 30871613 )
2019
15
Long Intergenic Non-Protein-Coding RNA 01138 Accelerates Tumor Growth and Invasion in Gastric Cancer by Regulating miR-1273e. ( 30902962 )
2019
16
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. ( 30902997 )
2019
17
Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. ( 30903518 )
2019
18
MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1. ( 30903594 )
2019
19
SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/β-catenin pathway. ( 30904482 )
2019
20
Laparoscopic modified lymphadenectomy in gastric cancer surgery using systematic mesogastric excision: a novel technique based on a concept. ( 30904933 )
2019
21
miR-106b Promotes Metastasis of Early Gastric Cancer by Targeting ALEX1 in Vitro and in Vivo. ( 30907988 )
2019
22
High-level expression of PRSS3 correlates with metastasis and poor prognosis in patients with gastric cancer. ( 30908656 )
2019
23
Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer. ( 30909185 )
2019
24
Clinical significance of serum miR-25 as a diagnostic and prognostic biomarker in human gastric cancer. ( 30909187 )
2019
25
Risk Factors of Gastric Cancer in High-Risk Region of China: A Population-Based Case-control Study ( 30909684 )
2019
26
Development and validation of a prognostic nomogram in gastric cancer with hepatitis B virus infection. ( 30909980 )
2019
27
The Zuo Jin Wan Formula increases chemosensitivity of human primary gastric cancer cells by AKT mediated mitochondrial translocation of cofilin-1. ( 30910056 )
2019
28
Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. ( 30910586 )
2019
29
Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy. ( 30910865 )
2019
30
Calponin 3 Regulates Cell Invasion and Doxorubicin Resistance in Gastric Cancer. ( 30911294 )
2019
31
Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer. ( 30911354 )
2019
32
Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. ( 30911769 )
2019
33
Laparoscopic distal gastrectomy for gastric cancer patient with intestinal malrotation: report of a case. ( 30911866 )
2019
34
Trend of Gastric Cancer Incidence in an Area Located in the Center of Iran: 2009-2014. ( 30911981 )
2019
35
Prediction of platinum-resistance patients of gastric cancer using bioinformatics. ( 30912200 )
2019
36
KLF9 suppresses gastric cancer cell invasion and metastasis through transcriptional inhibition of MMP28. ( 30913394 )
2019
37
Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer. ( 30913463 )
2019
38
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer. ( 30913874 )
2019
39
RNA N6-methyladenosine modification participates in miR-660/E2F3 axis-mediated inhibition of cell proliferation in gastric cancer. ( 30914234 )
2019
40
Ethnic Disparities in Gastric Cancer Presentation and Screening Practice in the United States: Analysis of 1997-2010 Surveillance, Epidemiology, and End Results-Medicare Data. ( 30914435 )
2019
41
Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins. ( 30915355 )
2019
42
Disseminated carcinomatosis of the bone marrow from gastric cancer during pregnancy. ( 30915672 )
2019
43
Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study. ( 30915908 )
2019
44
Glycitein induces reactive oxygen species-dependent apoptosis and G0/G1 cell cycle arrest through the MAPK/STAT3/NF-κB pathway in human gastric cancer cells. ( 30916421 )
2019
45
Extensive Intraoperative Peritoneal Lavage to Prevent Metastases From Gastric Cancer: The Elegance of Simplicity. ( 30916740 )
2019
46
Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Trial. ( 30916742 )
2019
47
C14orf159 suppresses gastric cancer cells' invasion and proliferation by inactivating ERK signaling. ( 30863180 )
2019
48
Comparing PET/MRI with PET/CT for Pretreatment Staging of Gastric Cancer. ( 30863443 )
2019
49
Nivolumab-induced interstitial lung disease in a patient with gastric cancer. ( 30863551 )
2019
50
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. ( 30863759 )
2019

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

76 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 92)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.6257C> G (p.Pro2086Arg) single nucleotide variant Uncertain significance rs786202975 GRCh37 Chromosome 5, 112177548: 112177548
2 APC NM_000038.5(APC): c.6257C> G (p.Pro2086Arg) single nucleotide variant Uncertain significance rs786202975 GRCh38 Chromosome 5, 112841851: 112841851
3 CDH1 NM_004360.4(CDH1): c.1296C> G (p.Asn432Lys) single nucleotide variant Uncertain significance rs187862045 GRCh37 Chromosome 16, 68847374: 68847374
4 CDH1 NM_004360.4(CDH1): c.1296C> G (p.Asn432Lys) single nucleotide variant Uncertain significance rs187862045 GRCh38 Chromosome 16, 68813471: 68813471
5 APC NM_000038.5(APC): c.95A> G (p.Asn32Ser) single nucleotide variant Uncertain significance rs539108537 GRCh37 Chromosome 5, 112090682: 112090682
6 APC NM_000038.5(APC): c.95A> G (p.Asn32Ser) single nucleotide variant Uncertain significance rs539108537 GRCh38 Chromosome 5, 112754985: 112754985
7 APC NM_000038.5(APC): c.3359G> A (p.Gly1120Glu) single nucleotide variant Pathogenic rs28933379 GRCh37 Chromosome 5, 112174650: 112174650
8 APC NM_000038.5(APC): c.3359G> A (p.Gly1120Glu) single nucleotide variant Pathogenic rs28933379 GRCh38 Chromosome 5, 112838953: 112838953
9 APC NM_000038.5(APC): c.3199C> T (p.Gln1067Ter) single nucleotide variant Pathogenic rs137854571 GRCh37 Chromosome 5, 112174490: 112174490
10 APC NM_000038.5(APC): c.3199C> T (p.Gln1067Ter) single nucleotide variant Pathogenic rs137854571 GRCh38 Chromosome 5, 112838793: 112838793
11 MTHFR NM_005957.4(MTHFR): c.665C> T (p.Ala222Val) single nucleotide variant drug response rs1801133 GRCh37 Chromosome 1, 11856378: 11856378
12 MTHFR NM_005957.4(MTHFR): c.665C> T (p.Ala222Val) single nucleotide variant drug response rs1801133 GRCh38 Chromosome 1, 11796321: 11796321
13 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
14 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
15 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
16 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh38 Chromosome 1, 45331556: 45331556
17 MUTYH NM_001128425.1(MUTYH): c.1213C> T (p.Pro405Ser) single nu